Flagship portfolio consolidation continues with Laronde-Senda

Flagship is again merging portfolio companies to form a new start-up, this time combining Laronde and Senda to create programmable medicines company Sail Biomedicines.

The union comes three years after Flagship rolled together four companies to create Senda Biosciences Inc. based on a common thread of developing medicines based on interactions between human and non-human cells. More recently, Senda had focused its attention on nanoparticles designed to deliver payloads such as translatable RNA into cells or tissues...